Various brands of Pistachio & Knafeh Milk Chocolate recalled due to Salmonella
Product: Pistachio & Knafeh Milk Chocolate
Issue: Food - Microbial contamination - Salmonella
Distribution:
Online
British Columbia
Ontario
Quebec
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
31 minutes ago
- Cision Canada
Triojection® from SpinaFX Granted Breakthrough Device Designation by U.S. FDA for Minimally Invasive Lumbar Disc Treatment
TORONTO, Aug. 15, 2025 /CNW/ - SpinaFX Medical Inc., ("SpinaFX") a leading innovator in image-guided interventional spine care, is proud to announce that its flagship device, Triojection®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This milestone acknowledges Triojection's potential to offer a highly effective, more accessible, and safer treatment for patients suffering from contained lumbar disc herniations, a condition recognized as one of the most common causes of disability worldwide. The Breakthrough Devices Program is designed to expedite the development and review of medical devices that demonstrate clear advantages over existing technologies for serious or life-threatening conditions. This designation grants SpinaFX prioritized access to the FDA, fostering a collaborative approach to regulatory processes and accelerating the path toward commercialization and clinical availability. A Technological Leap in Spine Care Triojection is a minimally invasive, image-guided procedure that leverages a proprietary oxygen-ozone delivery system to reduce pressure within the disc and alleviate nerve compression. Unlike more invasive surgical approaches or prolonged conservative treatments that may fail to provide relief, Triojection offers a targeted, outpatient solution that can be performed in a variety of healthcare settings from hospitals and ambulatory surgical centers to clinics in emerging markets. The device meets the FDA's stringent Breakthrough criteria: Providing a unique, novel and more effective treatment for patients with contained disc herniations. Representing a true technological innovation in the spinal care landscape. Demonstrating significant advantages in terms of safety, recovery time, cost, and accessibility. Showing strong potential to improve outcomes across diverse economic and geographic contexts, including under-resourced health systems. Meeting an Urgent Global Need Lumbar disc herniation affects millions of people globally and is a leading contributor to chronic pain, loss of mobility, reduced productivity, and diminished quality of life. Existing treatments often fall into two extremes: conservative care, which may not always bring relief, or invasive surgery, which carries risks, high costs, and extended recovery times. Triojection fills a critical therapeutic gap. It offers an evidence-based, low-barrier, cost-effective alternative that can be deployed rapidly and with minimal infrastructure ideal for both advanced and developing market health systems. "Our mission is to transform spine care and make meaningful minimalist solutions accessible to all," said Prof. Kieran Murphy MD, Chairman, Founder and Chief Medical Officer at SpinaFX. "This designation by the FDA validates the scientific merit of Triojection and 21 years of work by many people who have helped get us to this point. It's a vote of confidence in the future of inventiveness in spine health. We sincerely thank all our investors for their support and trust." Backed by Global Expertise and Scientific Rigor This regulatory milestone is the result of over two decades of research and development, including multiple international studies and collaborations with leading clinical experts in Italy, Switzerland, Greece, the United States and Canada. SpinaFX acknowledges the contributions of its diverse network of engineers and investigators, including Prof. Mario Muto (Italy) and Prof. Alexis Kelekis (Greece), both pioneers in the field of Interventional Neuroradiology. Clinical data supporting Triojection's efficacy continues to build, with upcoming publications expected to highlight its outcomes across multicenter trials. The company's engineering, regulatory, and clinical affairs teams along with trusted partners across Europe and the United States have played a critical role in advancing the technology toward approval and adoption. A Platform for Future Innovation Beyond this first indication, SpinaFX is exploring additional applications of its oxygen-ozone delivery platform in treating other disc-related conditions and musculoskeletal disorders. The company is also expanding its educational programs to train physicians in safe, effective, and evidence-based use of the Triojection procedure. "Our team is honored to receive this designation, but we view it as just the beginning," said Jeff Cambra, CEO of SpinaFX. "We're committed to working hand-in-hand with the FDA to bring Triojection to patients in the U.S. and beyond. Our goal is to create a new standard in spine care that's efficient, scalable, and deeply patient-centered. " About SpinaFX SpinaFX Medical Inc. is a Canadian-based medical technology company specializing in minimally invasive, image-guided therapies for spinal disorders. Its proprietary technology platform offers non-surgical solutions for treating disc-related conditions, using a unique approach to oxygen-ozone therapy. Committed to democratizing access to advanced spine care, SpinaFX collaborates with leading academic institutions, clinicians, and healthcare providers across the globe. Forward-Looking Statement This news release contains predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance, referred to herein as "forward-looking statements", which are made as of the date of this news release or as of the effective date of information described in this release, as applicable. The forward-looking statements address anticipated events or occurrences which may include economic factors, industry trends, market demand, and corporate performance and profitability, that may have an impact on SpinaFX's success. Forward-looking statements are often identified through words or expressions including "expects", "anticipates", "plans", "projects", "estimates", "envisages", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "can", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. All forward-looking statements are based on current beliefs as well as various assumptions made by, and information currently available to SpinaFX's management team. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections, and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. We caution any person reviewing this news release not to place undue reliance on these forward-looking statements as several important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. Neither SpinaFX nor its representatives undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by SpinaFX or its representatives or on behalf of either of them, except as may be required by law.
Toronto Sun
11 hours ago
- Toronto Sun
More Dubai chocolate brands recalled in salmonella outbreak linked to pistachios
Published Aug 14, 2025 • 1 minute read The Canadian Food Inspection Agency says several additional brands of Dubai pistachio and knafeh milk chocolate have been recalled. Photo by PHAC More recalls have been issued for a popular type of chocolate after a salmonella outbreak linked to certain brands of pistachios and pistachio-containing products. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account The Canadian Food Inspection Agency says several additional brands of Dubai pistachio and knafeh milk chocolate have been recalled. The brands are Chocofolie, Chocolato, Chocolats Favoris, Dubai and Vincent Selection. Read More The agency says the products were distributed in British Columbia, Ontario, Quebec and online. Other products that have been recalled in recent weeks include Habibi brand pistachio kernels, Al Mokhtar Food Centre pistachios, Dubai brand milk chocolate bars and Andalos brand baklava. At least 52 people have been sickened and 10 people sent to hospital since March after eating contaminated pistachios and baked goods containing the nut. RECOMMENDED VIDEO Toronto & GTA Toronto & GTA World Sunshine Girls Columnists
Cision Canada
14 hours ago
- Cision Canada
Young Mother's Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC
VANCOUVER, BC, /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to rheumatoid arthritis (RA) treatment by removing barriers that prevent patients from accessing the medications they truly need—barriers not found in many other provinces. Diagnosed with seropositive rheumatoid arthritis at just 29 years old, Eileen spent years searching for answers while coping with disabling pain, extreme fatigue, and the emotional toll of chronic illness. "By the time I was diagnosed, I was on the verge of being placed on long-term disability," Eileen recalls. "I had a toddler at home and every day was a struggle just to care for him." Forced to Wait While Suffering Like many RA patients in BC, Eileen's path to relief was slowed by a policy known as Step Therapy. Under Step Therapy, patients are required to try and 'fail' on older, less effective medications—sometimes for a year or more—before they can access modern treatments like biologics that offer the best chance for remission. "My doctor and I both knew these medications weren't likely to work for me, but we had no choice," Eileen says. "All that time, my disease kept progressing, and my hope for a normal life was slipping away." Eliminating these treatment delays remains a key priority for Arthritis Society Canada, the national organization leading advocacy, research, and support for the six million Canadians with arthritis. "There is no cure for arthritis. And because arthritis medications often require trial and error to find what works, speed of access is critical in preventing irreversible damage," says Trish Barbato, President and CEO of Arthritis Society Canada. "What works for one person may not work for another, and people often become resistant to treatment over time, making timely access to a range of medications even more essential." Eileen's story is far from unique. Arthritis is the leading cause of disability in North America, affecting people of all ages, and early access to the right treatment is critical. Yet in BC, restrictive policies leave many patients—especially younger adults—facing avoidable disability, work loss, and deteriorating health. A Personal and Systemic Cost The impact goes beyond the individual. Untreated or undertreated RA can lead to irreversible joint damage, increased healthcare use, and higher costs for the system as a whole. "If I'd had access to effective treatment earlier, I might still be working full-time," says Eileen. "Instead, I lost years to pain and fatigue, and my disease progressed much faster than it needed to." MedAccessBC Calls for Policy Change Eileen's experience underscores a larger, systemic issue that the Medicines Access Coalition – BC (MedAccessBC) has been fighting to address for over two decades. "Forcing patients to fail on older medications before approving access to newer, proven treatments is not only out of step with medical evidence—it's unfair and costly in the long run," says Jamie Myrah, Co-Chair of MedAccessBC. "All British Columbians deserve the opportunity for the best possible health outcomes, not arbitrary delays." As a non-profit coalition representing over 30 patient care organizations, MedAccessBC urges the BC government to review and update Step Therapy policies for rheumatoid arthritis and similar chronic conditions, ensuring that treatment decisions prioritize patient well-being and clinical best practices. A Call to Action Eileen's message to policymakers is clear: "Please give people like me a fighting chance to live, work, and participate fully in our communities. Timely access to the right medication isn't a luxury—it's a lifeline." About Rheumatoid Arthritis (RA) Rheumatoid arthritis is an autoimmune disease that causes the body's immune system to attack healthy joints and tissues. It can strike at any age and leads to pain, swelling, and fatigue. If not treated effectively and early, RA can result in severe disability, organ complications, and reduced life expectancy. There are more than 100 types of arthritis and related autoimmune conditions, affecting millions of Canadians. (Arthritis Society Canada) About the Medicines Access Coalition of BC MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program. About Arthritis Society Canada Arthritis Society Canada represents the six million people in Canada living with arthritis today, and the millions more who are impacted or at risk. Fueled by the trust and support of our donors and volunteers, Arthritis Society Canada is fighting arthritis with research, advocacy, innovation, information and support. We are Canada's largest charitable funder of cutting-edge arthritis research. We will not give up our efforts until everyone is free from the agony of arthritis. Arthritis Society Canada is accredited under Imagine Canada's Standards Program. For more information, visit
